Article Text

Download PDFPDF

2022-RA-823-ESGO FOXL2 mutation detection in circulating tumor DNA of adult granulosa cell tumors as a potential biomarker for disease monitoring from the randomized ALIENOR trial, a GINECO study
  1. Isabelle Treilleux1,
  2. Alexandra Lainé1,
  3. Valérie Combaret1,
  4. Cécile Dalban1,
  5. Laurence Gladieff2,
  6. Hortense Chevalier3,
  7. Magali Provansal4,
  8. Jean-Emmanuel Kurtz5,
  9. Fabien Brocard6,
  10. Frédéric Selle7,
  11. Pierre Etienne Heudel1,
  12. Patricia Pautier8,
  13. Michel Fabbro9,
  14. Anne Floquet10,
  15. Dominique Berton11,
  16. Aude-Marie Savoye12,
  17. Marianne Leheurteur13,
  18. Marie-Christine Kaminsky14,
  19. Sylvie Chabaud1 and
  20. Isabelle Ray-Coquard1
  1. 1Centre Léon Bérard, Lyon, France
  2. 2Institut Claudius Regaud, Toulouse, France
  3. 3Centre Oscar Lambret, Lille, France
  4. 4Institut Paoli Calmettes, Marseille, France
  5. 5ICANS-Institut cancérologie Strasbourg Europe, Strasbourg, France
  6. 6ORACLE – Centre d’Oncologie de Gentilly, Nancy, France
  7. 7Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France
  8. 8Institut Gustave Roussy, Villejuif, France
  9. 9ICM Val d’Aurelle, Montpellier, France
  10. 10Institut Bergonié, Bordeaux, France
  11. 11ICO – Centre René Gauducheau, Nantes, France
  12. 12Institut Jean Godinot, Reims, France
  13. 13Centre Henri Becquerel, Rouen, France
  14. 14ICL – Centre Alexis Vautrin, Vandoeuvre-lès-Nancy, France


Introduction/Background Adult granulosa cell tumors (aGCT) are rare ovarian malignant tumors harboring specific FOXL2 402C>G (C134W) mutation (96%) with multiples relapses. Serum markers are inaccurate in reflecting tumor burden, supporting the identification of new biomarkers.

Methodology Plasma samples were obtained at baseline and every 2–4 weeks for 6 months after C1D1 from patients enrolled in the ALIENOR trial (NCT01770301; 60 patients with relapsed sex cord-stromal tumors treated with chemotherapy +/- bevacizumab (Ray-Coquard, JAMA Oncol 2021)). Digital droplet PCR on circulating cell-free DNA was performed in 137 samples from 23 patients with FOXL2-mutated aGCT to investigate the clinical value of FOXL2 mutation on circulating tumor DNA (FOXL2mut ctDNA) for monitoring disease.

Results FOXL2mut ctDNA was detected in 10 of 23 aGCT patients’ plasma (43%). The sum of the largest diameter of target lesions was 52 mm for FOXL2mut ctDNA negative and 138 mm for positive samples. No clinical factors such as age, number of relapse, metastatic sites, chemotherapy lines or surgeries were correlated to FOXL2mut ctDNA levels. Looking at individual monitoring data, a trend between clinical progression and increased FOXL2mut ctDNA levels under therapy was noted. Among 19 patients with samples at baseline and for whom subsequent blood samples were also available at progression or end of study, sensibility, specificity, positive and negative predictive values of FOXL2mut ctDNA were 70%, 89%, 87% and 72% respectively. Only one of 4 patients without FOXL2mut ctDNA at baseline turned positive at progression. With a median follow-up of 42.6 months IC95%[36.8;48.8], 4 patients died (all in the FOXL2mut ctDNA group) (figure 1).

Abstract 2022-RA-823-ESGO Figure 1

Conclusion In this small series of aGCT, monitoring FOXL2mut ctDNA seems relevant to predict RECIST or clinical progression in relapse setting. All cancer deaths were in the FOXL2mut ctDNA group. Future studies are warranted to confirm if this biomarker can avoid repetitive CTscan for surveillance.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.